Interplay between integrin-linked kinase and ribonuclease inhibitor affects growth and metastasis of bladder cancer through signaling ILK pathways

Xiang Zhuang¹, Mengxin Lv¹, Zhenyu Zhong², Luyu Zhang³, Rong Jiang⁴ and Junxia Chen¹*

Abstract

Background: Integrin-linked kinase (ILK) is a multifunctional adaptor protein which is involved with protein signalling within cells to modulate malignant (cancer) cell movement, cell cycle, metastasis and epithelial–mesenchymal transition (EMT). Our previous experiment demonstrated that ILK siRNA inhibited the growth and induced apoptosis of bladder cancer cells as well as increased the expression of Ribonuclease inhibitor (RI), an important cytoplasmic protein with many functions. We also reported that RI overexpression inhibited ILK and phosphorylation of AKT and GSK3β. ILK and RI gene both locate on chromosome 11p15 and the two genes are always at the adjacent position of same chromosome during evolution, which suggest that ILK and RI could have some relationship. However, underlying interacting mechanisms remain unclear between them. Here, we postulate that RI might regulate ILK signaling pathway via interacting with ILK.

Methods: Co-immunoprecipitation, GST pull-down and co-localization under laser confocal microscope assay were used to determine the interaction between ILK and RI exogenously and endogenously. Furthermore, we further verified that there is a direct binding between the two proteins by fluorescence resonance energy transfer (FRET) in cells. Next, The effects of interplay between ILK and RI on the key target protein expressions of PI3K/AKT/mTOR signaling pathway were determined by western blot, immunohistochemistry and immunofluorescence assay in vivo and in vitro. Finally, the interaction was assessed using nude mice xenograft model.

Results: We first found that ILK could combine with RI both in vivo and in vitro by GST pull-down, co-immunoprecipitation (Co-IP) and FRET. The protein levels of ILK and RI revealed a significant inverse correlation in vivo and in vitro. Subsequently, The results showed that up-regulating ILK could increase cell proliferation, change cell morphology and regulate cell cycle. We also demonstrated that the overexpression of ILK remarkably promoted EMT and expressions of target molecules of ILK signaling pathways in vitro and in vivo. Finally, we found that ILK overexpression significantly enhanced growth, metastasis and angiogenesis of xenograft tumor; Whereas, RI has a contrary role compared to ILK in vivo and in vitro.

Conclusions: Our findings, for the first time, directly proved that the interplay between ILK and RI regulated EMT via ILK/PI3K/AKT signaling pathways for bladder cancer, which highlights the possibilities that ILK/RI could be valuable markers together for the therapy and diagnosis of human carcinoma of urinary bladder.

Keywords: Interplay, Integrin-linked kinase, Ribonuclease inhibitor, ILK pathway, Epithelial-mesenchymal transition, Bladder cancer cells

* Correspondence: chjunxia@126.com
1Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, China
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Integrin-linked kinase (ILK), a 59 kDa serine/threonine kinase, was discovered by detecting its interactions with the β1 integrin subunit [1]. ILK regulates a plethora of biological processes such as cell cycle, growth and angiogenesis; high expression of ILK enhances tumorigenesis [2, 3]. ILK directly phosphorylates AKT and GSK-3β to mediate β-catenin for oncogenesis [4]. Over-expression of ILK has a close relationship with prostate cancer, high-grade gastric cancer, and NSCLC (non-small cell lung cancer) [5–7]. In addition, it has been reported that increased expression of the protein is inversely related to the 5-year survival rate in prostate cancer [6]. ILK has important functions in promoting epithelial to mesenchymal transition (EMT) in mammary epithelium and the tumor invasion with a lower expression of E-cadherin [8, 9]. Using a selective inhibitor of ILK has been demonstrated to induce E-cadherin expression [10]. This is supposed to be an effective way to inhibit EMT [11]. However, the molecular basis for the high level expression and regulatory mechanism of ILK remain unclear in tumor.

Ribonuclease A (RNase A), a member of superfamily, has strong catalytic capability to the hydrolysis of RNA. When the protein reaches an optimal level, it might act as a passage of genetic information from DNA to protein via RNA. However, the protein at a higher concentration causes cell damage by resisting protein synthesis through increased ribonucleolytic activity. And this phenomenon aroused great interest of scientists in designing ribonuclease inhibitors [12–14]. Ribonuclease inhibitor (RI) is a 50 kDa horseshoe-shaped protein. It functions as the inhibitor of the ribonuclease activity of RNase A and angiogenin via a close interaction with them [15–18]. RI, also termed angiogenin inhibitor or RNH1, is abundant in the cell cytosol and also exits in mitochondria and nuclei [19]. The capacity of RI to protect genome integrity and cell viability from oxidized stress damage has been documented, and corresponds with the sensitivity to oxidation and the role of the protein in reactive oxygen species (ROS) scavenger in vitro [20–22]. RI, made up of 15 leucine-rich repeats (LRRs), emerges as a core protein in the research of LRRs. Its unique structure and function suggested that it could have a significant role in protein-protein interaction [23]. Therefore, we suppose that unknown biological functions exist in RI.

Human ILK gene and RNH1 gene both located at chromosome 11p15. In chromosome 3 of Drosophila, chromosome 7 of mice, chromosome 1 of rat and chromosome 11 of human, RI and ILK are always neighboring in the same chromosome. Depending on the chromosome proximity method, if the neighborhood of two genes is conserved in different genomes during evolution, they may have some related functions [24]. We have reported that ILK and RI had a co-localization and are negatively correlated in the EJ cells [25]. Our previous experiments also showed that RI down-regulated ILK and suppressed the phosphorylation of PKB/Akt and GSK-3β [26]. Therefore, these data suggest the possibility of the interaction between the two proteins. However, it’s unclear whether RI can directly bind to ILK. Furthermore, mechanism underlying the interaction between the two proteins has not been reported so far.

This research is aimed at further revealing the molecular mechanisms of interplay between ILK and RI as well as supplying new methods to the therapy of carcinoma of bladder. Here, we report that ILK could combine with RI to regulate its biological function in vivo and in vitro. This research first proved that direct binding of RI and ILK regulated EMT through ILK signaling pathway in bladder cancer. Our study may provide novel prognostic and therapeutic targets for bladder cancer.

Methods

Cell lines, animal and reagents
EJ cells, HEK 293 cells, pcDNA3.1(−)-myc-RI, pGEX-4 T-RI and pEGFP-C1-RI plasmids were conserved and prepared by our laboratory. pGEX-4 T-1 was bought from GE Healthcare China. pEYFP-N1 vector was from Clontech. pCMV-3xflag-CMVTM-10 was purchased from Sigma. BALB/C nude (nu/nu) mice were obtained from Beijing HFK Bioscience Company (Beijing, PR China). FBS was from TBD Science (Tianjin, PR, China). DMEM/High glucose medium, RPMI 1640 medium and G418 were purchased from Gibco-BRL (Carlsbad, CA, USA). Lipofectamine 2000 was bought from Invitrogen, Inc., (Carlsbad, California). Monoclonal mouse antibody of anti-human ILK was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit antihuman β-actin, CD31 antibody, Monoclonal primary rabbit antibody of anti-human PI3K, p-PI3K, PTEN, p- PTEN, Akt, p-Akt, GSK3β, p-GSK3β, mTOR, p-mTOR and β-catenin were obtained from Bioworld Technology, Inc. (St. Louis, USA). The rest of the primary antibodies are from Proteintech Group, Inc (Chicago, IL, USA). Cell Counting Kit-8 was bought from Genview Scientific, Inc (Craigieburn, VIC, AUS).

Construction of the plasmids
Human ILK cDNA sequence (accession number: NM_004517) was provided by the GenBank. The pEYFP-ILK and pCMV-3×Flag-ILK plasmids were constructed through the application of recombinant-DNA technology. The design for pEYFP-N1 plasmid (Clontech) primers was as follows: forward, 5′-CCGCTCGAGGCT ATGGACGACATTTTCAC-3′, and reverse, 5′-CGGA ATTCTCTTGTCTGATCATCTTCTCA-3′; The primers for pCMV-3xflag-CMV“-10 plasmid (Sigma) is following:
forward, 5'-CCCAAGCCTTATGGACGACATTTTCACCTC-3', and reverse, 5'-GCTCTAGACTACCTGTTGCTGCATCTTCCCACTG-3'. The recombinant plasmids pEYFP-N1-ILK was identified by using restriction enzymes Xho I and EcoR I (underlined), and the pCMV-3×Flag-ILK was identified by using restriction enzymes Hind III and Xba I (Italic). Finally, all plasmids were sequenced and then using BLAST software to verify the sequences.

Cell culture and establishment of stable cell lines
The EJ cells were cultured in RPMI 1640 media with 10 % FBS in a culture chamber containing 5 % CO₂ at 37 °C. The cells were collected and then inoculated into six well plates. Calculate the growth rate of the cells and enable them to grow until 80–90 % of the confluence on the next day. The cells were immediately transfected with the plasmids by Lipofectamine 2000. After 2 days, the choice was executed with 800 μg/ml of G418 for 2 weeks and 400 μg/ml of G418 for another 2 weeks. Finally, we selected the positive clones, and then proliferated stable cell lines that express ILK and the blank control vector which named EJ-ILK and EJ-FLAG cell respectively. Recombinant lentivirus containing RI (LV-RI) and control (LV-NC) were purchased from Western Biotechnology (Chongqing, PR, China). In order to establish the stable cell line, 2×10⁵ EJ cells were transfected with 4×10⁶ transducing units of lentiviruses, the supernatant was removed after 24 h and replaced with complete culture medium. After that, the EJ cells were selected with 2 μg/ml puromycin for two weeks. The two kinds of stable cell lines were named EJ-RI and EJ-LV5, respectively. HEK 293 cells were cultivated in DMEM/High glucose medium with 10 % FBS at 37 °C.

Western blot analysis
Immunoblot analysis was performed as following. Briefly, total cell protein lysates were obtained with RIPA buffer containing proteinase inhibitor (Sigma, St. Louis, MO, USA). The proteinof 30 μg was separated by appropriate concentration of SDS PAGE and shifted to PVDF membranes, then blocked, the membranes were incubated overnight with primary antibodies of AKT, p-AKT, GSK3β, p-GSK3β, PI3K, p-PI3K, PTEN, p-PTEN, mTOR, p-mTOR, β-catenin, E-cadherin, MMP2, MMP9, N-cadherin, Vimentin, Twist, Snail, S100A4, Smad2 and β-actinat at 4 °C. The proteins were separated and detected with Western blot using antibodies of AKT, p-AKT, GSK3β, p-GSK3β, PI3K, p-PI3K, PTEN, p-PTEN, mTOR, p-mTOR, β-catenin, E-cadherin, MMP2, MMP9, N-cadherin, Vimentin, Twist, Snail, S100A4, Smad2 and β-actinat at 4 °C. The emission intensities of 488-ILK and cy3-RI were monitored and recorded. The FRET efficiency (FRETe) was determined by computing the percentage of the 488-ILK fluorescence recovery [FRETe = (488-ILKA –488-ILKB)/488-ILKA × 100 %], where 488-ILKA was the 488 intensity after photobleaching and 488-ILKB was the 488 intensity before photobleaching of cy3.

GST pull down
The encoded RI-GST fusion proteins and the control GST proteins were expressed in BL21 cells after induction with IPTG. The GST-fusion proteins were arrested by glutathione-Sepharose 4B beads (GE Healthcare, Little Chalfont, UK) for the GST pulldown assays, and Flag-ILK (transfected EJ cells or HEK293 cells extracts) was added. Binding was performed for 3 h under rotation at 4 °C and the beads were washed with ice-cold PBS. The supernatant was loaded to gels followed by Western blot identification.

Co-immunoprecipitation assay (Co-IP)
For co-immunoprecipitation, EJ cells and HEK 293 cells were co-transfected with pCMV-3×Flag-ILK and pcDNA3.1(−)-myc-RI using Lipofectamine 2000 reagent (Invitrogen). Cells were trypsinized and rinsed in PBS. The protein extracts were then incubated using anti-Myc antibody and precipitated with protein A-agarose (Invitrogen). The precipitated proteins were separated and detected with Western blot using anti-RI or anti-ILK antibodies. Finally, the blots were visualized using ECL system (Amersham Biosciences).

Confocal microscope scanning and fluorescent resonance energy transfer (FRET) assay
To visualize interaction of ILK and RI in EJ cells, FRET imaging was conducted using cy3-conjugated goat anti-rabbit IgG and Alexa Fluor 488-conjugated goat anti-mouse IgG as biosensors. EJ cells were transfected with pCMV-3×Flag-ILK and pcDNA3.1(−)-myc-RI. And then conventional immunofluorescent assay was performed. Images of 488-ILK and cy3-RI FRET activities were acquired using a Leica confocal imaging spectrophotometer system (TCS-SP, Germany). Briefly, the fluorescence images for 488-ILK and cy3-RI were collected repetitively at a 10 s interval for five times. After that, cy3 was photobleached with full power of 543 nm line laser. The emission intensities of 488-ILK and cy3-RI were monitored and recorded. The FRET efficiency (FRETe) was determined by computing the percentage of the 488-ILK fluorescence recovery [FRETe = (488-ILKA –488-ILKB)/488-ILKA × 100 %], where 488-ILKA was the 488 intensity after photobleaching and 488-ILKB was the 488 intensity before photobleaching of cy3.

Co-colonization detection and immunocytofluorescence
EJ cells and 293 cells were co-transfected with plasmids pEYFP-N1-ILK and pEGFP-C1-RI using lipofection. The fluorescence proteins were visualized with Olympus multifunction microscope (Tokyo, Japan) equipped with appropriate filters (Chroma). Finally, images were captured and processed. The other way to detect location: EJ cells were co-transfected with...
plasmids pCMV-3 x Flag-ILK and pcDNA3.1(−)-myc-RI. After that, cells were fixed by 4 % paraformaldehyde, then permeabilized by Triton X-100. For detection of co-location, an antibody mix containing ILK (Santa Cruz, CA, USA) and RI was used. In co-immunostainings, goat anti-rabbit conjugated Alexa 594 and goat anti-mouse conjugated Alexa 488 were used and nuclei was stained with DAPI. Observations were performed and pictures were taken under Laser Scanning Confocal Microscope. For conventional IF assays, cells were incubated overnight at 4 °C in primary antibodies against ILK (Santa Cruz, CA, USA) and RI separately. And the IF was performed as described above.

Cell morphology, cell cycle and cell growth
The cells were grown on cover glass in 6-well plates, washed with PBS. The pictures of cells were taken under phase contrast inverted microscope (NIKON TE2000-U, Japan). For cell cycle assay, cells were trypsinized, washed by PBS, and then resuspended with 70 % ethanol and incubated on ice for 24 h. The distribution of cell cycle phase was assayed by flowcytometry (Becton Dickinson FACSCalibur, USA). Cell proliferation rate was determined by CCK-8 assay. Briefly, cells were seeded in 96-well plates. The cell proliferation was monitored every 24 h by CCK-8 assay. The medium were replaced with fresh medium containing 10 % CCK-8, shake the plates gently and then incubate them in 37 °C for 3.5 h. The absorbance value was detected by a plate reader at 450 nm. ALL of the assays above were repeated 3 times.

Mouse xenograft models, histology, immunohistochemistry and immunofluorescence
BALB/C nude mice used in these investigations were handled in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996). The animal production license and animal license of Chongqing Medical University are SCXK (Beijing) 2014–0004, SCXK (Chongqing) 2007–0001. The stable--transfected EJ cell lines (5 x 10^5) mixed with 1 x PBS were injected into the flank of nude mice (4-week-old) subcutaneously. Tumors and lungs were harvested 30 days after injection, the tumor tissue was weighed. The 4 μm tumor tissue sections were stained by HE (hematoxylin-eosin) and microvessels were numbered. The 5-μm-thick adhesion slides were dewaxed and then immersed in a gradient alcohol and washed three times. They were treated with 0.3 % H₂O₂ and then subjected to 10 % sheep serum for 30 min. The slides were incubated overnight with primary antibodies of RI, ILK, p-AKT, p-GSK3β, p-mTOR, β-catenin, E-cadherin, MMP2, MMP9, Vimentin, S100A4 and CD31. The next day, sections were incubated with fluorescein 594 and 488-conjugated secondary antibodies. Images were obtained using Olympus multifunction microscope (Tokyo, Japan).

Analysis of ILK and RI expression in tumor tissue from nude mice and human bladder cancer samples
Bladder carcinoma and corresponding non-tumor normal tissues were obtained from the first clinical college of Chongqing Medical University. All samples were de-identified. The 10-μm-thick frozen tumor tissue sections were fixed with acetone, blocked, and incubated overnight at 4 °C in primary antibodies against p-AKT, p-GSK3β, p-P13K, p-PTEN, p-mTOR, β-catenin, E-cadherin, MMP2, MMP9, Vimentin, S100A4 and CD31. The next day, sections were incubated with fluorescein 594 and 488-conjugated secondary antibodies. Images were obtained using Olympus multifunction microscope (Tokyo, Japan).

Statistical analysis
Data were processed with SPSS19.0 statistical software. The values were expressed as means ± SD. Student’s t tests were used for statistical analysis. P values of less than 0.05 were considered to be statistically significant.

Results
Over-expression of ILK and RI is identified
ILK gene sequence and vector were verified correctly by enzyme digestion, sequence analysis (data not shown). The transfected cells were selected, and then cloned, proliferated, finally verified by Western Blot and immuno-fluorescence assay. The expression of RI protein levels was significantly heightened in EJ-RI cells, compared with the other two control group cells respectively. The expression of ILK was observably increased in EJ-ILK cells, compared with the control group cells respectively (Fig. 1a). Immunofluorescence assay revealed that RI and ILK were brighter in EJ-RI and EJ-ILK cells respectively, compared with the corresponding control cells (Fig. 1b and c). The results demonstrated that RI or ILK were steadily expressed in the cells respectively.

ILK binds to RI in vivo and in vitro
To determine whether there is a direct interaction between ILK and RI, in vitro pull-down experiments were conducted. GST-RI constructs were used in pull-down assays with plasmids pCMV-3 x Flag-ILK. Western blot proved that ILK protein from EJ cells (Fig. 2a) and 293
cells (Fig. 2b) transfected pCMV-3 × flag-ILK and endogenous ILK could be captured by GST-RI and be pulled down specifically, demonstrating a physical binding of RI and ILK in vitro.

To further investigate the interplay of RI and ILK, we executed co-immunoprecipitation detection. RI and ILK were explored in immunoprecipitation complex with anti-myc antibodies. The results demonstrated that ILK and RI could have a binding and interaction (Fig. 2c and d).

Fluorescent resonance energy transfer and colocalization of ILK with RI are identified

To further detect real-time dynamic ILK-RI interaction in the living cell physiological conditions, we then applied FRET technology. As shown in the Fig. 3a, b, c and e, the FRET appeared between ILK and RI in EJ cells, which further confirmed the interaction between ILK and RI in living cells.

To investigate whether RI and ILK would localize in the same site of live cells for functional partners, we used vectors of GFP-RI fusion proteins and YFP-ILK fusion proteins. The subcellular localization of exogenous ILK and RI was observed in 293 and EJ cells under immunofluorescence microscopy. RI was green while ILK was red in both 293 cells and EJ cells. Then, we acquired the yellow merge figures (Fig. 3f). Furthermore, we performed IF assay to detect the localization. The immunofluorescence revealed that most of ILK distributed in cytoplasm (green). We also observed that RI was mainly spread in the cytoplasm (red). As a result, the yellow area which demonstrated that co-localization of ILK with RI existed in the cytoplasm (Fig. 3g).

Up-regulating RI or ILK affects cell morphology, cell cycle and proliferation

Live cells images showed that EJ-ILK cells became mesenchymal morphology and higher malignant phenotypes such as a larger nucleus and more division phases compared with other two control groups. Whereas, the cells in EJ-RI group revealed epithelial features and lower degree of malignant morphology (Fig. 4a).

The cell cycle was detected by flow cytometry. The graph displayed that the percentage of EJ-RI cells was increased by 71.24 % ± 6.89 % and 63.26 % ± 7.71 % in the S phase as well as it was decreased by 36.18 % ± 4.26 % and 35.82 % ± 3.66 % in the G1 phase, compared with the EJ cells and EJ-LV5 cell group, respectively. Meanwhile, the percentage of EJ-ILK cells was increased by 10.73 % ± 1.10 % and 10.41 % ± 1.70 % in the G1 as well as it was
decreased by 72.58 % ± 6.23 % and 70.08 % ± 10.40 % in the G2/M phase, compared with the EJ cells and EJ-FLAG cell group, respectively. However the EJ-RI in G2/M phase and EJ-ILK in S phase did not show significantly different. The results above showed that the growth of EJ-RI cells was prohibited with G1 phase decreasing and S phase arresting while ILK induced G2/M phase reducing and G1 phase increasing in the EJ cells (Fig. 4b and c).

The 450 nm absorbance is in accordance with the number of living cells. The Inhibition rates of EJ-RI cells to EJ vector cells, and the promoting rates of EJ-ILK to EJ vector cells were 29.41 and 35.29 % at 120 h respectively. Whereas, the growth of the control cells was not be affected, *P < 0.05. The A450 was observably decreased with CCK8 in the EJ-RI cells. The EJ-RI cells demonstrated lower cell proliferations than those of the EJ cells and the EJ-LV5 cells. As for EJ-ILK cells, the A450 was significantly increased with CCK8, compared with EJ cells and EJ-FLAG cells (Fig. 4d). According to the data, the reproductive capacity of the EJ-ILK cells strengthened obviously.

**Up-regulating RI or ILK affects the expressions of proteins associated with ILK signaling pathways and EMT**

To further investigate the molecular mechanism of RI and ILK in cell metastasis, we detected protein levels of the important target molecules of ILK pathway and EMT with Western blot. The expressions of AKT, GSK3β, PI3K and mTOR and did not significantly change. But, the levels of p-Akt, p-GSK3β, p-PI3K, p-mTOR and β-catenin were increased markedly in EJ-ILK cells whereas these protein levels decreased obviously in EJ-RI cells (*P < 0.05). MMP2, MMP9, N-cadherin, Vimentin, Twist, Snail and S100A4 were increased significantly in EJ-ILK cells whereas these protein levels decreased obviously in EJ-RI cells, compared with control group cells respectively (*P < 0.05). Furthermore, PTEN, E-cadherin and Smad2 expressions were obviously increased in the EJ-RI cells group, whereas these protein levels were down-regulated in the EJ-ILK cells group, compared with control groups respectively (Fig. 5a, b, c and d). Results show that the RI increase might be related with inhibition of the ILK signaling pathways and EMT. While, up-regulating ILK promoted ILK signaling pathways and EMT.

**Up-regulating RI or ILK affects tumor growth and experimental lung metastasis of BALB/C nude mice**

To further study to the effects of the RI and ILK on tumor growth respectively, 5 x 10⁵ various kinds EJ cells were inoculated subcutaneously into nude mice. HE staining and IF assay were conducted to further verify the influence of RI and ILK on tumor growth and
Fig. 3 (See legend on next page.)
metastasis. The rates of tumor formation were significantly lower in EJ-RI group compared with the other two control group cells, respectively. The rates of inhibitory tumors were 54.54 and 60.11 % compared with the EJ-LV5 and EJ cells groups. The tumors in the EJ-ILK cells groups were heavier than those in the other two control groups. The promoting rates of tumors were 222.22 and 200.94 % compared with the EJ-FLAG and EJ cells groups, respectively, *P < 0.05 (Fig. 6a and b).

The results showed that the ILK significantly facilitated the growth of bladder cancer, whereas, RI obviously suppressed xenograft tumor. The mice injected with EJ-RI cells displayed an obvious suppression of the metastasis with a substantial reduction of invasive tumor cells. Mice injected with EJ-ILK cell groups showed a remarkable increase of pulmonary metastatic nodules, compared with EJ and EJ-FLAG cells group (Fig. 6c). Microvessels of 5 different fields were counted under
microscope with the HE sections of tumor. EJ-ILK cells revealed more tumor microvessels compared with the control groups, whereas EJ-RI groups indicated fewer microvessels compared with the controls (*P < 0.05) (Fig. 6d and e). Immunofluorescent analyses of CD31 and S100A4 were conducted. Results displayed that the EJ-ILK cells group had a higher CD31 and S100A4 expression and apparent increase of angiogenesis; whereas weaker CD31 and S100A4 expression and fewer microvessels were observed in the EJ-RI groups (Fig. 6f).

**Up-regulating RI or ILK affect the expressions of proteins associated with ILK signaling target molecules and EMT in tumor tissue**

Immunohistochemical and immunofluorescent detections were conducted to determine the impacts of ILK and RI expression on ILK signaling pathways and EMT in tumors respectively. The results revealed that EJ-ILK cells group showed much lower RI and E-cadherin levels as well as stronger positive signal of ILK, p-Akt, p-GSK3β, p-PI3K, p-PTEN, p-mTOR, β-catenin, MMP2, MMP9 and Vimentin in tumor tissue, whereas lower ILK, p-Akt, p-GSK3β, p-PI3K, p-PTEN, p-mTOR, β-catenin, MMP2, MMP9 and Vimentin expression were observed in tumor tissue of the EJ-RI groups (Fig. 7). These results were consistent with analysis in vitro, suggesting that the interaction between RI and ILK could be related with regulation of ILK signaling pathway and EMT.

High ILK and low RI protein levels are observed in tumor tissue of nude mice and human bladder cancer

To gain insights into the expression of ILK and RI in tumor tissue from nude mice and human bladder cancer,
we performed immunofluorescent assay to determine the two kinds of protein level in the specimens. The data suggest that ILK expression was negatively correlated with RI levels in the bladder cancer specimens from nude mice and human. Human tumor and nude mice xenograft tumor tissues showed the expression of ILK was increased while the expression of RI was inhibited (Fig. 8a and b). The fact that higher level of RI and lower level of ILK in paired normal tissues suggest that RI could be required to regulate ILK for suppression of bladder cancer.

**Discussion**

Invasive or metastatic bladder cancer is a lethal disease in spite of surgery, radiation treatment and chemotherapy. Unfortunately, transurethral resection or other adjuvant treatments do not achieve much in preventing tumor metastasis and recurrence. Finally, 20–30 % of those tumors progress into more aggressive tumors and cause death of patients [27, 28].

Protein-protein interaction plays a critical role in every essential biological process. Human ribonuclease inhibitor (RI) contains 15 Leucine-rich repeats (LRRs). Such repeats have been considered to have multiple functions, such as extracellular matrix interaction, cell-cycle regulation, DNA repair and enzyme inhibition [17]. Therefore, we speculate that RI might still have some undiscovered biological roles. Our previous study showed that ILK and RI have a common subcellular location, and the expression of RI was negatively correlated with ILK in BIU-87 cells [29]. Yet, correlation between RI and ILK has not been fully understood. ILK plays an important role in transducing many of the biochemical signals that are triggered by cell-matrix interactions and modulate
fundamental processes such as growth, survival, differentiation, invasion and angiogenesis. In vertebrates, loss-of-function analyses have highlighted the importance of ILK in the regulation of protein-protein interactions that are related to the activation of signaling pathways. The further study of ILK will emphasize on its function of the direct and indirect interactions existing in ILK. Which interaction is more important for normal tissue depends on which interaction is more crucial for the development of human malignant tumors. As a matter of fact, if ILK could be effectively targeted, the upper proposition will be proved and valued properly [30–32]. However, it is unknown whether there is also an interaction between ILK and RI in cancer progression and the mutual relationship has remained unclear so far.

Here, we first reported that RI and ILK have a physical interaction between them, and we use colocalization analysis, co-immunoprecipitation and pull-down assays to prove the hypothesis. We also found for the first time that RI could suppress ILK activity by extremely tight combination in vitro. RI contains leucine-rich repeats (LRRs), which have vast surface areas to supply protein interaction [23].

In this study, we also showed that ILK could promote the cell proliferation, change cell morphology and regulate cell cycle. Meanwhile, we demonstrated that over-expression RI decreased the proliferation and led to cell cycle arrest in S phase. Moreover, we also showed that over-expression of ILK remarkably promotes the phosphorylation of signaling targets AKT, GSK-3β, PI3K and

Fig. 7 Up-regulating RI and ILK regulates the expressions of ILK signaling pathway molecules and EMT-related proteins in vivo. a Immunofluorescent sections were stained in tumor xenograft tissue with rabbit anti-human p-Akt (S473), p-GSK3β (S9) p-PI3K, p-PTEN, p-mTOR, β-catenin, E-cadherin, MMP2, MMP9 and Vimentin respectively, then were incubated with Alexa Fluor 594 Goat Anti-Rabbit IgG or Alexa Fluor 488 Goat Anti-Rabbit IgG secondary antibody. EJ-ILK cell groups resulted in significantly higher p-Akt, p-GSK3β, p-PI3K, p-PTEN, p-mTOR, β-catenin, MMP2, MMP9 and Vimentin as well as lower E-cadherin expressions in tumor tissue, compared with EJ and EJ-FLAG cells groups. In contrast, weaker p-Akt, p-GSK3β, p-PI3K, p-PTEN, p-mTOR, β-catenin, MMP2, MMP9 and Vimentin expression were detected in tumor tissue of the EJ-RI cell groups along with stronger E-cadherin expressions, which was in accordance with experiments in vitro (magnification × 200). b Immunohistochemical sections stained with mouse anti-human ILK, rabbit anti-human RI, p-Akt(S473), p-GSK3β(S9), p-mTOR, β-catenin, E-cadherin, MMP2, MMP9 and Vimentin respectively, the nuclei were counterstained by hematoxylin (magnification 400×). Representative images demonstrated that the EJ-RI cell groups had a weaker brown immunostain for ILK, p-Akt, p-GSK3β, p-mTOR, β-catenin, MMP2, MMP9 and Vimentin as well as a stronger positive signal for RI and E-cadherin in cytoplasm compared with the control group cells respectively. EJ-ILK cells group revealed much lower RI and E-cadherin expressions as well as stronger positive signal of ILK, p-Akt, p-GSK3β, p-mTOR, β-catenin, MMP2, MMP9 and Vimentin expressions in tumor tissue (magnification × 400).
mTOR in vivo and vitro. ILK/AKT/mTOR signaling pathway is widely known for modulating cell growth, differentiation, apoptosis, cellular metabolism and cancer cell survival. ILK phosphorylated Akt to play an important role in anti apoptosis through direct phosphorylation of downstream target protein; ILK also phosphorylate GSK-3β to inhibit its activity, then make the beta catenin dephosphorylate in the steady state. The beta catenin is accumulated and activates LEF/Tcf to promote transcription, which can enable the expression of AP-1 and prompt expression of CyclinD1 and MMP-9 expression and so on. The changes could result in proliferation, invasion and metastasis of tumor cells [33–35]. Meanwhile, we also detected some crucial target molecules to assess whether that RI regulates ILK signaling pathways is truly very efficient. The results revealed that RI suppressed the expression of the ILK and phosphorylation of PKB/Akt, GSK-3β and other important molecules in this signaling pathway. Moreover, the results indicated that PTEN expressions were significantly increased in EJ-RI cells, but phosphorylated PTEN was up-regulating in EJ-ILK cells groups, compared with control group cells respectively. PTEN was activated due to decrease of phosphorylated PTEN level, and then inhibited downstream AKT activation. The role of PTEN is serving on a tumor suppressor gene by suppressing Akt/PKB signaling pathway. The activity of ILK is suppressed by phosphatases such as ILKAP and PTEN [36], our results agree with this research.

To gain invasive capabilities, tumor cells go through a morphology and physiology change such as EMT. The invasion of cancer cells is remarkably affected by EMT [33]. Firstly, we showed that up-regulating ILK leads to the cell phenotype from epithelial to mesenchymal morphological changes. Secondly, in this study, we showed that ILK increase caused a decrease of E-cadherin as epithelial cell marker and an ascent of Vimentin and N-cadherin as mesenchymal markers, and enhanced the expression of Snail and Twist as EMT inducer. The most obvious change of EMT is the down-regulating E-cadherin and the acquisition the expression of EMT regulators such as Snail, Slug and Twist [37]. Thirdly, We also showed that over-expression of ILK could increase the protein level of MMP-2 and MMP-9. It has been reported MMPs have something to do with EMT in cancer progression [38]. our experiment results supported the view that ILK is an important regulator of EMT [39]. Conversely, we demonstrated that RI affected the expressions of these EMT-related proteins in EJ cells, the results showed that over-expression of RI remarkably restrained EMT of EJ cells, which is in line with previous report [40].

Finally, the animal model experiment demonstrated that ILK significantly promoted growth and metastasis of transplanted tumor; tumors of EJ-ILK cell group were

Fig. 8 Expressions of ILK and RI in tumor tissue from nude mice and human bladder cancer are detected. a Tumor tissues from nude mice were stained with mouse anti-human ILK and rabbit anti-human RI antibodies separately. b HE staining of human bladder tissue sections were conducted and photographs were taken under microscope (magnification × 400). Human bladder tumor tissue and adjacent normal bladder tissue were incubated in the antibodies mixed with mouse anti-human ILK and rabbit anti-human RI antibodies. Bladder tumor tissue from both nude mice and human showed higher ILK expression as well as lower RI expression, whereas the expressions of RI and ILK in adjacent normal bladder tissue were just the opposite (magnification × 200)
heavier and the microvascular density is higher than those in the control groups. Direct down-regulation of ILK caused a reduction of endothelial cell growth and blood vessel formation in vivo [41]. Moreover, fewer metastases of the lung were detected in the EJ-RI group; and that, EJ-ILK cell groups showed a remarkable invasion and metastases. In particular, we found the expression of S100A4 markedly enhanced in EJ-ILK cells group compared other groups in vivo and vitro. S100A4 secreted by tumor and stromal cells, is a member of the S100 calcium-binding protein family. It can support tumorigenesis by triggering angiogenesis. Recently, S100A4 has attracted the attention of researchers because its expression is related to the movement, invasion, metastasis, angiogenesis and prognosis of various tumors [42], which agree well with our findings. Our study also proved that RI inhibited ILK expression and suppressed angiogenesis both in vivo and in vitro. Interestingly, our observation on the human pathological specimens consistently revealed that RI and ILK negatively correlated in tumor and non-tumor tissues, which is corresponding to in vitro and animal experiments.

Conclusions
Taken together, for the first time, our data demonstrated that RI might regulate the function of ILK through mutual binding. Therefore, we propose that RI could suppress tumorigenesis, EMT and metastasis by regulating ILK mediated signal pathway. The data provided evidence that ILK could be a valuable therapeutic and diagnostic target for bladder cancer. Our research also highlights the possibilities that RI could serve as a promising anti tumor protein and angiogenesis inhibitor. Further research will be required to verify the underlying molecular mechanism of the interaction between ILK and RI.

Funding
This study was supported by grants from National Natural Science Foundation of China (81372203 and 81172424). The funding body play roles in the design of the study and execution as well as collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
Most data generated or analysed during this study are included in this published article, other data are available from the corresponding author on reasonable request.

Authors’ contributions
XZ and MXL conducted all experiments and analyzed the data, ZYZ provided pathology evaluation. LYZ and RJ provided support with experimental techniques. JXC and XZ wrote the manuscript. JXC conceived the project and supervised all experiments. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This research involving human tissue samples and animals was approved by the Ethics Committee of Chongqing Medical University, and informed consent was obtained from each patient.

Author details
1Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, China. 2The First Clinical College, Chongqing Medical University, Chongqing 400016, China. 3Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, China. 4Laboratory of Stem Cells and Tissue Engineering, Chongqing Medical University, Chongqing, China.

Received: 11 July 2016 Accepted: 17 August 2016

Published online: 30 August 2016

References
1. Hännigian GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature. 1996;379:91–6.
2. Wang S, Baisson MD. Integrin-linked kinase: a multi-functional regulator modulating extracellular pressure-stimulated cancer cell adhesion through focal adhesion kinase and Akt. Cell Oncol. 2009;31:273–89.
3. Shibue T, Brooks MW, Weinberg RA. An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell. 2013;24:481–98.
4. Kalra J, Dragovska WH, Bally MB. Using pharmacokinetic profiles and digital quantification of stained tissue microarrays as a medium-throughput, quantitative method for measuring the kinetics of early signaling changes following integrin-linked kinase inhibition in an in vivo model of cancer. J Histochem Cytochem. 2015;63:691–709.
5. Gu X, Xing X, Yang W, Hu J, Dai D. High expression of integrin-linked kinase predicts aggressiveness and poor prognosis in patients with gastric cancer. Acta Histochem. 2014;116:755–62.
6. Graff JR, Deddens JA, Konicek BW, Colligan BM, Huntz BM, Carter HW, et al. Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res. 2001;7:1987–91.
7. Abd El-Rehim DM, Abd-Elghany MI, Nazmy MH. Integrin-linked kinase, snail and multidrug resistance protein 1: three concordant players in the progression of non-small cell lung cancer. J Egypt Natl Canc Inst. 2015;27:129–37.
8. Gil D, Ciołczyk-Wierzbicka D, Dulinska-Litewka J, Zwawa K, McCubrey JA, Laidler P. The mechanism of contribution of integrin linked kinase (ILK) to epithelial-mesenchymal transition (EMT). Adv Enzyme Regul. 2011;51:195–207.
9. Eger A, Stockinger A, Park J, Langkof E, Mikula M, Gotzmann J, et al. beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FoSR-induced epithelial to mesenchymal transition. Oncogene. 2004;23:2672–80.
10. Tan C, Costello P, Sanghera J, Domínguez D, Baulida J, de Herreros AG, et al. Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-LeF/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in AP C−/− human colon carcinoma cells. Oncogene. 2001;20:133–40.
11. Thiery JP, Acloque H, Huang FY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.
12. Raines RT. Ribonuclease A, Chem Rev. 1998;98:1045–66.
13. Ledoux L. Action of ribonuclease on two solid tumours in vivo. Nature. 1955;176:36–7.
14. Datta D, Dasgupta S, Pathak T. Ribonuclease A inhibition by carboxymethylsulfonyl-modified xylo- and arabinopyrimidines. Chemmedchem. 2014;9:2138–49.
15. Matsushima N, Tachi N, Kuruki Y, Enkhbayar P, Osaki M, Kamiya M, et al. Structural analysis of leucine-rich-repeat variants in proteins associated with human diseases. Cell Mol Life Sci. 2005;62:2771–91.
16. McEwan PA, Scott PG, Bishop PN, Bella J. Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol. 2006;155:294–305.
17. Datta D, Samanta A, Dasgupta S, Pathak T. 3’-Oxo-, amino-, thio- and sulfone-acetamide modified thymines: effect of increased acidity on ribonuclease A inhibition. Bioorg Med Chem. 2013;21:4634–45.
et al. Journal of Experimental & Clinical Cancer Research (2016) 35:130

18. Kobe B, Deisenhofer J. Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature. 1993;366:751–6.
19. Furia A, Moscato M, Cali G, Pizzo E, Confaloni E, Amoroso MR, Esposito F, Nitsch L, D’Alessio G. The ribonuclease/angiogenin inhibitor is also present in mitochondria and nuclei. FEBS Lett. 2011;585:613–7.
20. Cui XY, Fu PF, Pan DN, Zhao Y, Zhao J, Zhao BC. The antioxidative effects of ribonuclease inhibitor. Free Radic Res. 2003;37:1079–85.
21. Wang S, Li H. Radical scavenging activity of ribonuclease inhibitor from cow placenta. Biochemistry (Mosc). 2006;71:520–4.
22. Monti DM, Montesano Gesuldi N, Matteucci J, Esposito F, D’Alessio G. The cytosolic ribonuclease inhibitor contributes to intracellular redox homeostasis. FEBS Lett. 2007;581:930–4.
23. Nekrasov AN, Zinchenko AA. Structural features of the interfaces in enzyme-inhibitor complexes. J Biomol Struct Dyn. 2010;28:85–96.
24. Gherman A, Wang R, Avarnopoulos D. Orientation, distance, regulation and function of neighboring genes. Hum Genomics. 2009;3:143–56.
25. Zhu J, Pan X, Zhang Z, Gao J, Zhang L, Chen J. Downregulation of integrin-linked kinase inhibits epithelial-to-mesenchymal transition and metastasis in bladder cancer cells. Cell Signal. 2012;24:1323–32.
26. Li L, Pan XY, Shu J, Jiang R, Zhou YJ, Chen JX. Ribonuclease inhibitor up-regulation inhibits the growth and induces apoptosis in murine melanoma cells through repression of angiogenin and ILK/PI3K/AKT signaling pathway. Biochimie. 2014;103:89–100.
27. Eifler JB, Scarpato KR, Clark PE. Management of noninvasive bladder cancers. Curr Opin Oncol. 2015;27:185–90.
28. Patel SG, Cohen A, Weiner AB, Steinberg GD. Intravesical therapy for bladder cancer. Expert Opin Pharmacother. 2015;16:889–901.
29. Gao J, Zhu J, Li HY, Pan XY, Jiang R, Chen JX. Small interfering RNA targeting integrin-linked kinase inhibited the growth and induced apoptosis in human bladder cancer cells. Int J Biochem Cell Biol. 2011;43:1294–304.
30. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 2005;5:551–63.
31. Esfandiarei M, Suarez A, Amaral A, Si X, Rahmani M, Dedhar S, et al. Novel role for integrin-linked kinase in modulation of coxsackievirus B3 replication and virus-induced cardiomyocyte injury. Circ Res. 2006;99:354–61.
32. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase–essential roles in physiology and cancer biology. J Cell Sci. 2008;121:3121–32.
33. Jang MJ, Baek SH, Kim JH. UCH-L1 promotes cancer metastasis in prostate cancer cells through repression of angiogenin and ILK/PI3K/AKT signaling pathway. Cell Signal. 2012;24:1323–32.
34. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012;30:777–82.
35. Hausmann G, Tenne A, Cordes N, B€uker I, ILKAP, ILK and PINCH1 control cell survival of p53-wildtype glioblastoma cells after irradiation. Oncotarget. 2015;6:34592–605.
36. Conde-Perez A, Gros G, Longvert C, Pedersen M, Petit V, Aktar Z, et al. A caveolin-dependent and PI3K/AKT-independent role of PTEN in beta-catenin transcriptional activity. Nat Commun. 2015;6:8093.
37. Sabe H. Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor beta signalling. J Biochem. 2011;149:633–9.
38. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201–12.
39. Yang J, Hou Y, Zhou M, Wen S, Zhou J, Xu L, et al. Twist induces epithelial-mesenchymal transition and cell motility in breast cancer via ITGB1-FAK/ILK signaling axis and its associated downstream network. Int J Biochem Cell Biol. 2015;71:62–71.
40. Pan X, Yong D, Yao X, Xin Y, Zhang L, Chen J. Up-regulating ribonuclease inhibitor inhibited epithelial-to-mesenchymal transition and metastasis in murine melanoma cells. Int J Biochem Cell Biol. 2012;44:998–1008.
41. Wani AA, Jafarnajd SM, Zhou J, Li G. Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kappaB/Interleukin-6 signaling pathway. Oncogene. 2011;30:2778–88.
42. Li WL, Zhang Y, Liu BG, Du Q, Zhou CX, Tian XS. Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer. Exp Ther Med. 2015;10:1983–9.